Press Releases August 28, 2026 03:15 PM

Rainier Acquisition Corporation Announces Closing of $75,000,000 Initial Public Offering

Rainier Acquisition Corporation Completes $75 Million IPO to Fund Future Life Sciences Acquisitions

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
RNAQU

Rainier Acquisition Corporation, a newly formed special purpose acquisition company (SPAC), has closed its initial public offering (IPO) raising $75 million. The company, trading on Nasdaq under RNAQU, aims to pursue mergers or acquisitions primarily in the global life sciences sector including therapeutics, diagnostics, and genomics.

Rainier Acquisition Corporation Announces Closing of $75,000,000 Initial Public Offering
RNAQU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Successfully raised $75 million in IPO through issuance of 7.5 million units at $10 each.
  • Focus on acquiring businesses in life sciences sectors such as therapeutics, diagnostics, genomics, and precision medicine.
  • The IPO securities are listed on the Nasdaq Capital Market with separate trading for shares and warrants to begin soon.

NEW YORK, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Rainier Acquisition Corporation (the "Company") announced today the closing of its initial public offering of 7,500,000 units consisting of one Class A ordinary share and one-quarter of one redeemable warrant at a price of $10.00 per unit. The offering generated gross proceeds to the Company of $75,000,000, before underwriting discounts and offering expenses. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units began trading on the Nasdaq Capital Market on August 27, 2026 under the ticker symbol “RNAQU.” Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on The Nasdaq Capital Market under the symbols "RNAQ" and "RNAQW," respectively.

The Company is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, although its efforts to identify a prospective target business will not be limited to any particular industry or geographical region. The Company's management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer.

Chardan acted as the sole book-running manager for the offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 1,125,000 units at the initial public offering price to cover over-allotments, if any.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at: [email protected].

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on August 26, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including with respect to the Company's search for an initial business combination. No assurance can be given that the offering will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Gbola Amusa, Chief Executive Officer
1 Pennsylvania Plaza, Suite 4800
New York, NY 10119
Tel.: (646) 465-9000
[email protected]


Risks

  • No assurance that Rainier Acquisition Corporation will complete a business combination or acquire a suitable target company, presenting investment uncertainty.
  • Forward-looking statements and use of proceeds are subject to risks outside management's control, including regulatory risks and market conditions.
  • If a business combination is not completed within a specified timeframe, there could be adverse effects to investors and the company's viability.

More from Press Releases

B2Gold Reports Fatality at the Masbate Gold Project Aug 28, 2026 Hudbay Files Early Warning Report for Panoro Minerals Ltd. Aug 28, 2026 Norwood Financial Corp Adopts Stock Repurchase Program Aug 28, 2026 Arq Appoints Peter Owino as Chief Accounting Officer Aug 28, 2026 Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update Aug 28, 2026